GAITHERSBURG, Md.--(BUSINESS WIRE)--Jan. 27, 2006--GenVec, Inc. (Nasdaq:GNVC) announced today that Dr. Neil Senzer, Medical Director of the Mary Crowley Research Center, located in Dallas, Texas, has presented long-term follow-up data on the Phase II study of GenVec’s investigational oncology drug, TNFerade, at the American Society of Clinical Oncology’s Gastroenterological Cancer Symposium, currently in session in San Francisco. In oral and poster presentations, Dr. Senzer discussed results from a regimen in which 24 patients with locally advanced, resectable esophageal cancer were treated prior to surgery with chemotherapy, radiation, and TNFerade injections to the tumor in doses ranging from 4x10e8 p/u to 4x10e11 p/u.
